The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Isomeride     N-ethyl-1-[3- (trifluoromethyl) phenyl]propa...

Synonyms: Adipomin, Ponderex, Rotondin, Obedrex, Redux, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dexfenfluramine


Psychiatry related information on Dexfenfluramine


High impact information on Dexfenfluramine


Chemical compound and disease context of Dexfenfluramine


Biological context of Dexfenfluramine


Anatomical context of Dexfenfluramine


Associations of Dexfenfluramine with other chemical compounds


Gene context of Dexfenfluramine

  • METHODS: Prolactin (PRL) and cortisol (CORT) responses to the serotonergic agonist d-fenfluramine (D-fen), clinical psychobehavioral changes, and psychometric measures were evaluated 3 weeks and then 12 months after MDMA discontinuation [31].
  • Administration of m-chlorophenylpiperazine and fenfluramine, both of which induce anorexic effects via 5-HT2C receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old A(y) mice, whereas the anorexic effects were attenuated in food-restricted A(y) mice [32].
  • Yeast-expressed recombinant human CYP2D6 metabolized dexfenfluramine with high affinity (Km 1.6 microM, Vmax 0.18 nmol min(-1) nmol P450(-1)) to nordexfenfluramine which was the sole product observed [33].
  • We were able to identify CYP2D6 (high affinity) and CYP1A2 (low affinity) as the major enzymes catalysing the N-dealkylation of dexfenfluramine in human liver microsomes [33].
  • CONCLUSION(S): The lower PRL response to fenfluramine in the stress-sensitive animals suggests that stress-sensitive individuals have decreased activity in central serotonergic neurons [34].

Analytical, diagnostic and therapeutic context of Dexfenfluramine


  1. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. Mark, E.J., Patalas, E.D., Chang, H.T., Evans, R.J., Kessler, S.C. N. Engl. J. Med. (1997) [Pubmed]
  2. Valvular heart disease associated with dexfenfluramine. Cannistra, L.B., Davis, S.M., Bauman, A.G. N. Engl. J. Med. (1997) [Pubmed]
  3. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. Weissman, N.J., Tighe, J.F., Gottdiener, J.S., Gwynne, J.T. N. Engl. J. Med. (1998) [Pubmed]
  4. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Coccaro, E.F., Siever, L.J., Klar, H.M., Maurer, G., Cochrane, K., Cooper, T.B., Mohs, R.C., Davis, K.L. Arch. Gen. Psychiatry (1989) [Pubmed]
  5. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Hollander, E., DeCaria, C.M., Nitescu, A., Gully, R., Suckow, R.F., Cooper, T.B., Gorman, J.M., Klein, D.F., Liebowitz, M.R. Arch. Gen. Psychiatry (1992) [Pubmed]
  6. Controlling panic attacks with fenfluramine. Solyom, L. The American journal of psychiatry. (1994) [Pubmed]
  7. Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Davidoff, R., McTiernan, A., Constantine, G., Davis, K.D., Balady, G.J., Mendes, L.A., Rudolph, R.E., Bowen, D.J. Arch. Intern. Med. (2001) [Pubmed]
  8. Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. Jones, H., Curtis, V.A., Wright, P., Lucey, J.V. The American journal of psychiatry. (1998) [Pubmed]
  9. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. Khan, M.A., Herzog, C.A., St Peter, J.V., Hartley, G.G., Madlon-Kay, R., Dick, C.D., Asinger, R.W., Vessey, J.T. N. Engl. J. Med. (1998) [Pubmed]
  10. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. Jick, H., Vasilakis, C., Weinrauch, L.A., Meier, C.R., Jick, S.S., Derby, L.E. N. Engl. J. Med. (1998) [Pubmed]
  11. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., Bégaud, B. N. Engl. J. Med. (1996) [Pubmed]
  12. Serotonin depletion by fenfluramine in the carcinoid syndrome. Stahl, S.M., Levin, B. N. Engl. J. Med. (1982) [Pubmed]
  13. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity. Anchors, M. Arch. Intern. Med. (1997) [Pubmed]
  14. Central serotonin activity and aggression: inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Coccaro, E.F., Kavoussi, R.J., Cooper, T.B., Hauger, R.L. The American journal of psychiatry. (1997) [Pubmed]
  15. Prolactin and cortisol responses to fenfluramine in Parkinson's disease. Kostić, V.S., Lecić, D., Doder, M., Marinković, J., Filipović, S. Biol. Psychiatry (1996) [Pubmed]
  16. Redox redux: the control of oxidative stress responses. Demple, B., Amábile-Cuevas, C.F. Cell (1991) [Pubmed]
  17. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Launay, J.M., Hervé, P., Peoc'h, K., Tournois, C., Callebert, J., Nebigil, C.G., Etienne, N., Drouet, L., Humbert, M., Simonneau, G., Maroteaux, L. Nat. Med. (2002) [Pubmed]
  18. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Weir, E.K., Reeve, H.L., Huang, J.M., Michelakis, E., Nelson, D.P., Hampl, V., Archer, S.L. Circulation (1996) [Pubmed]
  19. Neurobiology of an anorectic drug: fenfluramine. Rowland, N.E., Carlton, J. Prog. Neurobiol. (1986) [Pubmed]
  20. Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. Lucas, J.J., Yamamoto, A., Scearce-Levie, K., Saudou, F., Hen, R. J. Neurosci. (1998) [Pubmed]
  21. Life and death in germinal centers (redux). Kelsoe, G. Immunity (1996) [Pubmed]
  22. Myelin repair: developmental myelination redux? Balabanov, R., Popko, B. Nat. Neurosci. (2005) [Pubmed]
  23. Action of fenfluramine on voltage-gated K+ channels in human pulmonary-artery smooth-muscle cells. Wang, J., Juhaszova, M., Conte, J.V., Gaine, S.P., Rubin, L.J., Yuan, J.X. Lancet (1998) [Pubmed]
  24. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Mann, J.J., McBride, P.A., Brown, R.P., Linnoila, M., Leon, A.C., DeMeo, M., Mieczkowski, T., Myers, J.E., Stanley, M. Arch. Gen. Psychiatry (1992) [Pubmed]
  25. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Lyons, W.E., Mamounas, L.A., Ricaurte, G.A., Coppola, V., Reid, S.W., Bora, S.H., Wihler, C., Koliatsos, V.E., Tessarollo, L. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  26. Valvular heart disease associated with fenfluramine-phentermine. Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., Schaff, H.V. N. Engl. J. Med. (1997) [Pubmed]
  27. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. McCann, U.D., Seiden, L.S., Rubin, L.J., Ricaurte, G.A. JAMA (1997) [Pubmed]
  28. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Sulzer, D., Rayport, S. Neuron (1990) [Pubmed]
  29. Neuroendocrine response to fenfluramine challenge in boys. Associations with aggressive behavior and adverse rearing. Pine, D.S., Coplan, J.D., Wasserman, G.A., Miller, L.S., Fried, J.E., Davies, M., Cooper, T.B., Greenhill, L., Shaffer, D., Parsons, B. Arch. Gen. Psychiatry (1997) [Pubmed]
  30. Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats. Storlien, L.H., Thorburn, A.W., Smythe, G.A., Jenkins, A.B., Chisholm, D.J., Kraegen, E.W. Diabetes (1989) [Pubmed]
  31. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Gerra, G., Zaimovic, A., Ferri, M., Zambelli, U., Timpano, M., Neri, E., Marzocchi, G.F., Delsignore, R., Brambilla, F. Biol. Psychiatry (2000) [Pubmed]
  32. Hyperphagia Alters Expression of Hypothalamic 5-HT2C and 5-HT1B Receptor Genes and Plasma Des-Acyl Ghrelin Levels in Ay Mice. Nonogaki, K., Nozue, K., Oka, Y. Endocrinology (2006) [Pubmed]
  33. Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. Haritos, V.S., Ching, M.S., Ghabrial, H., Gross, A.S., Taavitsainen, P., Pelkonen, O., Battaglia, S.E., Smallwood, R.A., Ahokas, J.T. Pharmacogenetics (1998) [Pubmed]
  34. Sensitivity to stress-induced reproductive dysfunction linked to activity of the serotonin system. Bethea, C.L., Pau, F.K., Fox, S., Hess, D.L., Berga, S.L., Cameron, J.L. Fertil. Steril. (2005) [Pubmed]
  35. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. Gardin, J.M., Weissman, N.J., Leung, C., Panza, J.A., Fernicola, D., Davis, K.D., Constantine, G.D., Reid, C.L. JAMA (2001) [Pubmed]
  36. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. Gardin, J.M., Schumacher, D., Constantine, G., Davis, K.D., Leung, C., Reid, C.L. JAMA (2000) [Pubmed]
  37. International trial of long-term dexfenfluramine in obesity. Guy-Grand, B., Apfelbaum, M., Crepaldi, G., Gries, A., Lefebvre, P., Turner, P. Lancet (1989) [Pubmed]
WikiGenes - Universities